Brief: Nkgen Biotech Announces FDA Clearance Of Investigational New Drug Application To Treat Alzheimer’S Disease
24/10/2023 14:17
Oct 24 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR SNK01 NK CELL THERAPY TO TREAT ALZHEIMER’S
DISEASE
* NKGEN BIOTECH - NKGEN'S NEURODEGENERATIVE PROGRAM
CONTINUES TO
ADVANCE WITH DOSING IN PHASE 1/2A CLINICAL TRIAL ANTICIPATED TO
START BY YEAR-END 2023
* NKGEN BIOTECH INC - APPROVED TRIAL OF 30 PATIENTS WITH
MODERATE
AD WILL LOOK TO COMMENCE BEFORE END OF THIS YEAR
* NKGEN BIOTECH INC - FIRST INTERIM DATA IS EXPECTED IN
EARLY Q3
2024
Source text for Eikon: ID:nGNX37697k
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program